Company intelligence / Profile preview

AAVantgarde Bio

Milan, Lombardy, Italy

Ownership: Private
Development stage: Phase 1

Overview

The company has dosed patients in a first-in-human Phase 1/2 study for USH1B with safety data published from the first two subjects. Additional patients have been dosed at low and mid-dose cohorts. The Stargardt disease program has completed IND-enabling studies with an IND filing anticipated soon and first patient dosing expected Q3 2025. No approved products yet.

Therapeutic areas: OphthalmologyNeurology
Modalities: Adeno-associated virus (AAV) gene therapylarge-gene delivery using proprietary dual hybrid and intein-mediated platforms
Industry: Biotech

Drug pipeline

4 assets

AAVB-081

3 more assets in the full pipeline.

Request access →

Partnerships

Notable investors include Sofinnova Partners, Atlas Venture, Forbion, Longwood FundPlatform open to potential partnerships for additional indications.

Beyond the preview

Go deeper on AAVantgarde Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AAVantgarde Bio.

Explore the full profile